Clinical Trials Browser

Phase 1/2 × Breast Neoplasms × Telmisartan × Clear all

NCT07370506 2026-01-29

Telmisartan for Prevention of Doxorubicin-Induced Cardiotoxicity in Breast Cancer Patients

Phase 1/2 Not yet recruiting

Breast Neoplasms